ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the ...

Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow enhancements. JENA, (Germany), SHANGHAI, (China), | 27 ...

The device offers a shortened procedure time and efficient, effective SMILE for patients with myopia, with or without ...

Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow JENA, Germany and SHANGHAI, Feb. 26, 2025 /PRNewswire/ ...

Aligne Wealth Advisors Investment Management (AWAIM) proactively manages risk and return opportunities as markets evolve. This forward-looking approach recently led to strategic portfolio adjustments ...

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included ...

Despite revenue growth and strategic advancements, Carl Zeiss Meditec AG (CZMWF) faces margin pressures and market uncertainties, particularly in China.

Nevertheless, we were able to post slight growth thanks to the DORC acquisition. The good response to the new products, the approval of our VISUMAX ® 800 refractive laser system for the Chinese market ...

However, Goldman Sachs no longer sees further downside risk to consensus estimates, particularly following the earlier-than-expected approval of Visumax 800 in China. This regulatory approval is ...

The good response to the new products, the approval of our VISUMAX ® 800 refractive laser system for the Chinese market and the general recovery in order entry and order backlog give us ...

Felton's outlook is somewhat buoyed by the recent approval of Visumax 800 in China, which occurred earlier than anticipated. This development could potentially mitigate further downside risks to ...

Customers are waiting for the new Kinevo 900S, which became available in the US and Europe in late 2024, and Visumax 800, which was recently approved in China and should be available for purchase ...